We Are Your Vaccine Partner
Taurus Vaccines LLC specializes in the development of innovative vaccines utilizing a unique technological platform developed by its sister company, Capricorn Technologies GmbH. Our vaccines are based on a safe, potent, and adjuvanting double-attenuated influenza virus vector. This platform induces strong cytotoxic T lymphocyte (CTL) responses, effectively protecting immunized animals against rapidly evolving viruses and other pathogens. Additionally, the vector supports a robust humoral immune response targeting conserved B-cell epitopes.
Our Approach to Vaccine Development.
Philosophy
The induction of stable populations of cytotoxic T-cells capable of eliminating infected host cells at the early stages of viral infection—accompanied, when necessary, by mucosal or systemic neutralizing IgA or IgG antibodies—enables the prevention of not only respiratory diseases but also a broad range of other infections from their earliest stages.
Unique Vector Platform
UniFluVec™ and its derivates represent our main vector platform offering induction of stable, robust CTL and humoral response against inserted pathogen’s sequences to create stable (6< months) populations of cytotoxic memory cells.
Design of Vaccines in silico
To generate effective CTL responses against pathogen-specific sequences, we utilize proprietary, novel informatics methods developed specifically for our needs by the informatics division of our partner company. The algorithms in EpiQuest Suite v5 enable the identification and design of CTL epitopes capable of inducing high-affinity cytotoxic T-cell responses, thereby eliciting biologically active cytotoxic T-lymphocytes.
